Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Antonio De Vivo"'
Autor:
Antonio De Vivo, Giovanni Marconi, Nicola Tumedei, Elisa Luicchini, Maria Chiara Finazzi, Ilaria Maria Burgo, Gian Luca Forni, Silvia Linari
Publikováno v:
Italian Journal of Medicine, Vol 18, Iss 2 (2024)
Gaucher disease (GD) is a rare genetic disorder characterized by glucocerebrosidase deficiency. Over 50% of patients with mild disease go undiagnosed, suggesting that GD diagnosis rates are still significantly low despite advancements in medical know
Externí odkaz:
https://doaj.org/article/ec284c6d1979463bae51f723483260f8
Autor:
Michele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, Massimiliano Bonifacio, Fabio Stagno, Gianni Binotto, Mariella D’Adda, Monia Lunghi, Monica Crugnola, Maria Luisa Ferrari, Francesca Lunghi, Fausto Castagnetti, Gianantonio Rosti, Roberto M. Lemoli, Rosaria Sancetta, Maria Rosaria Coppi, Maria Teresa Corsetti, Giovanna Rege Cambrin, Atelda Romano, Mario Tiribelli, Antonella Russo Rossi, Sabina Russo, Lara Aprile, Monica Bocchia, Lisa Gandolfi, Mirko Farina, Simona Bernardi, Nicola Polverelli, Aldo M. Roccaro, Antonio De Vivo, Michele Baccarani, Domenico Russo
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1726-1737 (2021)
Abstract Background Intermittent treatment with TKIs is an option for the great majority (70%–80%) of CML patients who do not achieve a stable deep molecular response and are not eligible for treatment discontinuation. For these patients, the only
Externí odkaz:
https://doaj.org/article/b182193348604dd0987cace12205f347
Autor:
Corrado, Girmenia, Wilma, Barcellini, Paola, Bianchi, Eros, Di Bona, Anna Paola, Iori, Rosario, Notaro, Simona, Sica, Alberto, Zanella, Antonio, De Vivo, Giovanni, Barosi, Antonio, Risitano
Publikováno v:
Blood Reviews. 58:101013
This article presents the results of group discussion among an ad hoc constituted panel of experts aimed at identifying and addressing unmet clinical needs (UCNs) in the management of infectious risk associated with eculizumab or new terminal complem
Publikováno v:
Italian Journal of Medicine, Vol 5, Iss 2, Pp 90-97 (2013)
The authors conducted a systematic review of the medical literature published in the past 15 years on the myelodysplastic syndromes (MDSs). The MDSs are typically seen in the elderly, and primary and secondary forms can be distinguished. This heterog
Externí odkaz:
https://doaj.org/article/5d11ef3a66fa4700b525b1fcdecc05fd
Autor:
José Mendes Aldrighi, Sidney Carvalho Fernandes, Ana Paula Pantoja Margeotto, Marco Antonio De Vivo Barros, Anita Lr Saldanha, Tania Leme da Rocha Martinez, André Luis Valera Gasparoto
Publikováno v:
Journal of Cardiology & Current Research. 14:46-48
Publikováno v:
Geological Society, London, Special Publications. 466:155-170
Autor:
Michele Baccarani, Daniela Cilloni, Michela Rondoni, Emanuela Ottaviani, Francesca Messa, Serena Merante, Mario Tiribelli, Francesco Buccisano, Nicoletta Testoni, Enrico Gottardi, Antonio de Vivo, Emilia Giugliano, Ilaria Iacobucci, Stefania Paolini, Simona Soverini, Gianantonio Rosti, Francesca Rancati, Cinzia Astolfi, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli
Publikováno v:
Haematologica, Vol 92, Iss 9 (2007)
Background and Objectives The hypereosinophilic syndrome (HES) may be associated with the fusion of the platelet derived growth factor receptor α (PDGFRα) gene with the FIP1L1 gene in chromosome 4 coding for a constitutively activated PDGFRα tyros
Externí odkaz:
https://doaj.org/article/f1e8c6f7854a47f498415da19526214b
Autor:
Michele Cavo, Simona Soverini, Roberto Marasca, Carmela Anna Maria Tomaselli, Antonio De Vivo, Miriam Fogli, Monica Crugnola, Donato Mannina, Elena Trabacchi, Sergio Siragusa, Maurizio Musso, Fabio Stagno, Isabella Capodanno, Michele Baccarani, Patrizia Tosi, Stefana Impera, Giovanni Martinelli, Alessandro Zironi, Riccardo Ragionieri, Marzia Salvucci, Fausto Castagnetti, Francesco Cavazzini, Gianantonio Rosti, Francesco Fabbiano, Paolo Vigneri, Giuseppe Mineo, Francesco Di Raimondo, Michele Rizzo, Caterina Musolino, Antonio Spitaleri, Gabriele Gugliotta, Agostino Antolino
Publikováno v:
American Journal of Hematology. 92:82-87
Chronic myeloid leukemia (CML) treatment is based on company-sponsored and academic trials testing different tyrosine kinase inhibitors (TKIs) as first-line therapy. These studies included patients selected according to many inclusion-exclusion crite
Autor:
Simona Soverini, Serena Merante, Ilaria Iacobucci, Simonetta Pardini, Gianatonio Rosti, Sabina Russo, Ivana Pierri, Michele Malagola, Fabio Stagno, Antonio De Vivo, Miriam Fogli, Patrizia Pregno, Giuliana Alimena, Sara Barulli, Monia Lunghi, Valeria Cancelli, Elena Trabacchi, Mario Annunziata, Cristina Skert, Monica Bocchia, Giovanni Martinelli, Franco Mandelli, A. M. Liberati, Michele Baccarani, Elisabetta Abruzzese, Mario Tiribelli, Federica Cattina, Massimo Breccia, Alessandra Iurlo, Domenico Russo, Gianmatteo Pica, Fausto Castagnetti
Publikováno v:
American Journal of Hematology. 89:119-124
Interferon a (IFNa) prolongs survival of CML patients achieving CCyR and potentially synergizes with TKIs. We report on the molecular status and long term outcome of 121 patients who were treated in Italy between 1986 and 2000 with IFNa based therapy